Startup profile for Dialytix: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Dialytix funding, valuation and investors

UAB spinout Kidney Cloud platform for real-time kidney disease care management and dialysis ops.

Keep track of Dialytix

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Accelerator

$60K · April 2024

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$60K

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

pre seed · Birmingham, AL

Investors in latest funding

Lead: Prosper HealthTech Accelerator

Sources: latest funding Last verified: 2026-07-26

Overview

Dialytix builds the Kidney Cloud platform — a federated kidney disease care management system that integrates real-time multimodal data from electronic health records, dialysis devices, and financial systems for quality improvement, operational efficiency, and capacity management. Founded in 2023 as a UAB-connected spinout (leadership includes Rubin Pillay and co-founder/CEO Ruben Raposo), the company is headquartered in Birmingham, AL. In April 2024 Dialytix was one of five health-tech startups awarded $60,000 each through the Prosper HealthTech Accelerator.

Why Dialytix is interesting

Kidney care is data-fragmented across EHRs, dialysis machines, and finance systems. Dialytix — a 2023 UAB faculty spinout — productizes that multimodal feed as Kidney Cloud, and entered Birmingham’s Prosper HealthTech accelerator with a $60K award in April 2024.

Product & use cases

Kidney Cloud aggregates device-agnostic dialysis and EHR data into dashboards and analytics for quality assurance, capacity, and financial performance in kidney disease programs.

  • Dialysis and nephrology programs needing a 360° patient/ops view
  • Hospitals tracking CRRT and AKI care KPIs across machines and EHRs
  • Health systems reducing nurse data-entry burden between devices and finance

Key facts

  • Kidney Cloud: multimodal kidney/dialysis data platform (EHR + devices + finance)
  • UAB faculty spinout founded 2023; HQ Birmingham, AL
  • Prosper HealthTech Accelerator (Apr 2024): $60K award among five health-tech startups
  • Collaborations around AI clinical decision support for AKI/CRRT reported with UAB clinicians

Funding history (newest first)

Investors in our directory

Funds linked from Dialytix's profile — open a fund page for stage focus and related deal articles.

Competitive landscape

Edge: Kidney-specific, device-agnostic multimodal integration — narrower and deeper than general hospital analytics suites.

  • Dialysis machine vendor analytics incumbent

    Often siloed to one device ecosystem.

  • General EHR/ops dashboards adjacent

    Broad BI without kidney/device fusion focus.

Industries

Market / IPO context

Editorial / static context — not a live quote.

Related funding articles

Venture Capital Tracker pieces that cover Dialytix's financing or category context.

FAQs about Dialytix

Practical answers founders, operators, and investors typically search for.

Dialytix’s Kidney Cloud platform integrates EHR, dialysis device, and financial data for kidney disease care quality, ops, and capacity management.
Birmingham, AL.
Yes — founded in 2023 as a UAB faculty-led / UAB-connected health-tech startup.
Dialytix’s product name for its federated kidney disease data and AI platform.
Prosper HealthTech Accelerator (/fund/prosper-healthtech-accelerator) awarded Dialytix $60K in April 2024 as part of its Birmingham cohort.
Pre-seed / early private company.
2023.
Kidney care and dialysis programs that need real-time multimodal data across clinical devices and hospital systems.
Dialytix positions as device-agnostic and multi-source (EHR + finance + machines), not locked to one dialysis OEM.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.